New research may indicate a potential advantage of buprenorphine use for opioid-use disorder (OUD) during pregnancy instead of methadone.
New Brunswick, New Jersey — Led by Elizabeth A. Suarez, PhD, MPH, from the Rutgers Institute for Health, Health Care Policy and Aging Research, new research may indicate a potential advantage of buprenorphine use for opioid-use disorder (OUD) during pregnancy instead of methadone. Maternal and neonatal outcomes were investigated among a cohort of pregnant women, with lower infant-related risks seen in connection with buprenorphine use.
Buprenorphine has already been shown to be of potential use for individuals soon to initiate treatment for OUD, and the current research utilized Medicaid data on such maternal-related outcomes as cesarean delivery and pregnancy complications and such infant-related outcomes as neonatal abstinence syndrome and low birth weight.
“It’s essential for the general public to understand the importance of OUD treatment during pregnancy to avoid harms associated with lack of treatment,” Suarez noted. “These results may guide clinical recommendations for people with OUD who are pregnant or are hoping to be pregnant.”
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
2 Commerce Drive
Cranbury, NJ 08512